Prelude Capital Management’s Twist Bioscience TWST Stock Holding History

Prelude Capital Management’s Portfolio TWST Stock Details TWST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.95M	Sell	18,976 -2,711	-13%	-$176K	0.14%	183
2026 Q1	$1.03M	Sell	21,687 -348	-2%	-$15.6K	0.08%	298
2025 Q4	$699K	Buy	+22,035	New	+$687K	0.05%	414
2022 Q1	–	Sell	-2,773	Closed	-$215K	–	2245
2021 Q4	$215K	Sell	2,773 -327	-11%	-$33.6K	0.01%	1527
2021 Q3	$332K	Buy	+3,100	New	+$355K	0.01%	1088
2021 Q2	–	Sell	-5,324	Closed	-$659K	–	1971
2021 Q1	$659K	Sell	5,324 -1,704	-24%	-$259K	0.02%	776
2020 Q4	$993K	Sell	7,028 -3,286	-32%	-$365K	0.03%	481
2020 Q3	$784K	Sell	10,314 -12,566	-55%	-$782K	0.04%	315
2020 Q2	$1.04M	Buy	+22,880	New	+$821K	0.06%	313

Other funds holding TWST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Prelude Capital Management's TWST Position: Q2 2026 in Review

Prelude Capital Management reduced its Twist Bioscience (TWST) stake by 13% in Q2 2026, selling an estimated $176K and leaving 18,976 shares worth $1.95M. The position accounts for 0.14% of the portfolio, ranked #183.

Prelude Capital Management first reported a position in TWST in Q2 2020 and has held it in 9 quarters since. 336 funds tracked by Wall St. Rank hold TWST as of Q2 2026.

Prelude Capital Management held 18,976 shares of Twist Bioscience worth $1.95M as of Q2 2026.
Prelude Capital Management sold 2,711 Twist Bioscience shares in Q2 2026, an estimated $176K.
Twist Bioscience made up 0.14% of Prelude Capital Management's portfolio in Q2 2026, its #183 holding.
Prelude Capital Management first reported a position in Twist Bioscience in Q2 2020 and has held it in 9 quarters since.
336 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.